D2C pharma brands must ensure their cash-pay programs and telehealth ties are transparent and compliant with anti-kickback laws.

Patients want medication clarity and cost help earlier—pharma brands can step up with timely info, not just ads.

Marc Cuban Cost Plus Drug online pharmacy founder Mark Cuban wants the Trump administration to waive generic drug regulatory approval fees, the entrepreneur told Reuters. Cuban’s push into US manufacturing could help lower prices for some high-cost generic drugs by adding competition where little currently exists.

Agentic AI company Infinitus is rolling out new tools designed to boost pharma companies’ direct-to-consumer (D2C) platforms. As pharmaceutical companies move to sell drugs directly to patients, the immediate next step is raising awareness and making their online platforms easy to use. It’s not just about selling a medicine—it’s about building relationships, ensuring patients don’t discontinue treatment, and providing a better healthcare experience than what consumers are typically used to.

Novo Nordisk is dropping the cash-pay price of its blockbuster GLP-1 drugs Wegovy and Ozempic from $499 per month to $349 for existing patients. Novo is betting on lower prices to lure some patients away from Zepbound. However, Lilly’s D2C strategy for Zepbound is working—the drugmaker said that about 35% of new Zepbound prescriptions are from the self-pay channel. It’s a signal that most patients who are prescribed Zepbound aren’t asking to switch to Wegovy. That could shift if the price gap between the two drugs widens.

Eli Lilly is offering cash-pay pricing for its weight loss drug Zepbound at Walmart. This is the first time Lilly has offered a retail pharmacy pick-up option to customers who order Zepbound through LillyDirect. Walmart will soon be the only retail pharmacy where customers paying cash for Novo’s and Lilly’s GLP-1 weight loss drugs can pick up their prescriptions. This will help the company benefit from increased foot traffic as more of Lilly’s customers enter its stores.

Hims & Hers and GoodRx each moved into new categories of prescription drug sales. Hims and Hers is now offering care for menopause and perimenopause under its Hers brand, while GoodRx launched a subscription for men’s hair loss treatment. GoodRx is a new player in an expanding market of companies selling prescription drugs, but we think the company has staying power. GoodRx’s vast user base offers a cheaper, more efficient path to converting consumers into subscription members than other D2C healthcare competitors.

AstraZeneca reached a deal with the US government to lower prescription drug prices in exchange for a three-year tariff reprieve. If more Big Pharma deals with Trump mirror Pfizer’s and AstraZeneca’s, it signals the sector views the terms as favorable, since core revenue drivers remain largely untouched. Still, pricing pressure won’t subside anytime soon, with more drugs expected to be up for Medicare price negotiations. Big Pharma shouldn’t view these latest agreements as the end of the line, but rather as important learning moments for which drug pricing concessions will appease the administration.

Novo Nordisk is partnering with Costco to offer the retailer’s members Ozempic and Wegovy for $499 per month, or about half off what the medications cost patients without insurance. Novo tapping into Costco’s customer base of over 100 million US cardholders is a savvy play, especially considering that Costco members skew toward higher-income compared with shoppers generally. Novo and Costco can specifically market to new mothers and families broadly who may be struggling with weight gain due to their busy lives.

The Trump administration is putting off plans to impose a 100% tariff on drug imports as it continues negotiations with pharma companies to lower prices on their brand-name products. Earlier this week, Pfizer became the first to strike a deal with the administration that will cut many of its drug prices by 40% or more, and in return, receive a three-year delay on tariffs. Other drugmakers can win from a PR perspective and gain political favor by striking similar agreements that avoid the worst-case scenario of heavy tariffs, drawn-out legal battles, or regulatory cost controls on all of their pharma products.

The news: Pharma commercialization company Eversana bought digital health tech Waltz Health and is creating direct-to-consumer (D2C) and direct-to-payer models that cut out rebate negotiators, or pharmacy benefit managers (PBMs). Our take: D2C sales are the most palatable of the Trump administration’s drug pricing policies for pharma companies. But with limited in-house tech expertise, drugmakers need to partner with service providers. Health tech companies that offer D2C end-to-end solutions can create new revenue streams, while helping pharmas cater to Trump and patients’ demand for affordability and convenience.

ESPN has launched its long-awaited direct-to-consumer subscription app, consolidating 12 networks and sports rights under one platform. Two tiers—ESPN Select at $11.99/month and ESPN Unlimited at $29.99/month—offer up to 79,000 live events annually, with Unlimited subscribers gaining access to marquee programming like Monday Night Football and NBA games. A Disney+/Hulu bundle is also available for $35.99/month, discounted in year one. Features include multiview, betting tools, live stats, fantasy integrations, and an AI-powered personalized SportsCenter. The move signals an existential reset for ESPN, aiming to convert cable loyalists and younger fans while stabilizing growth in a cord-cutting era.

Direct-to-consumer (D2C) ecommerce is evolving, driven by Gen Z’s shopping habits and the rise of powerful AI tools.

The situation: Nike’s turnaround will likely take some time. In FYQ4, the company’s sales fell 12% YoY (11% on a constant-currency basis), reflecting what CFO Matthew Friend called the “largest financial impact” from the company’s reset strategy. Still, he expressed confidence that “headwinds will moderate from here,” emphasizing Nike’s focus on execution and controlling what it can. Our take: Turning around a company the size of Nike is like trying to turn around an ocean liner in rough waters. Change takes time, especially amid headwinds like tariffs and shaky demand, and execution missteps keep dragging on performance. Nike is adjusting course—leaning back into wholesale, cleaning up its inventory, and getting more surgical with product drops—but calm seas are still a ways off.

US retail and ecommerce sales growth will take a hit in 2025 as unpredictable changes in tariff policies ripple through the economy, shaking consumer confidence.

Direct-to-consumer (D2C) brands like Eyebuydirect are overcoming traditional barriers in high-consideration purchase categories like eyewear.

On today’s podcast episode, we discuss how to get folks to buy something they can’t go and see in a store, how D2Cs should be thinking about generative AI, and how one DTC is negotiating the tariff minefield. Listen to the conversation with our Senior Analyst Sara Lebow as she hosts Principal Analyst Sky Canaves and CEO and president of Eyebuydirect Sunny Jiang.

Williams-Sonoma buys Dormify’s IP: The move aims to help the housewares retailer capture a larger share of the college-age consumer market.

ESPN’s new platform marks a bold digital pivot: Meanwhile, Fox is launching Fox One to stay competitive in the streaming era.

Acadia acquires Crush to expand Amazon-first capabilities: The deal reflects growing demand for full-funnel retail media solutions.